hugo24
Bluelighter
- Joined
- Mar 23, 2005
- Messages
- 867
Duloxetin weakkly blocks the Dopamin Transporter ( 240nm;0.8nm SERT,7.5nm NET) and inhibits DA uptake,maybe its sufficient clinically,at least it appears quite effective (personal experience,but f*** the withdrawal)
http://www.nature.com/npp/journal/v25/n6/full/1395741a.html
Desvenlafaxine (Pristiq) will come to market soon,but it appears more a patent related thing.Venlafaxine is still a bit a mystery to me,not really a SNRI,rather a SSRI, surely more selective than Fluoxetin.Altough in vivo it wins some in selectivity (see same link above).What I'm still missing is the claim for its DRI property in high doses and the alledged "push",maybe its also a metabolite responsible for it?One paper claimed an anti-pain effect,which is antagoniseable with Naloxone,how come that when it doesen't bind to opioid receptors?
http://www.nature.com/npp/journal/v25/n6/full/1395741a.html
Desvenlafaxine (Pristiq) will come to market soon,but it appears more a patent related thing.Venlafaxine is still a bit a mystery to me,not really a SNRI,rather a SSRI, surely more selective than Fluoxetin.Altough in vivo it wins some in selectivity (see same link above).What I'm still missing is the claim for its DRI property in high doses and the alledged "push",maybe its also a metabolite responsible for it?One paper claimed an anti-pain effect,which is antagoniseable with Naloxone,how come that when it doesen't bind to opioid receptors?
